2025-03-24 - Analysis Report
## UnitedHealth Group Inc. (UNH) Stock Analysis

**0) Introduction:** This report analyzes UnitedHealth Group Inc. (UNH), a diversified healthcare company providing a range of healthcare products and services, based on provided financial data.  We will examine performance relative to the S&P 500 (VOO), recent price movements, key indicators, earnings, and financial statements.


**1) Performance Comparison with S&P 500:**

UNH's cumulative return is significantly higher than the S&P 500's.

* **UNH Cumulative Return:** 135.64%
* **VOO (S&P 500) Cumulative Return:** 104.98%
* **Return Difference:** 30.66%

The provided relative divergence of 40.1% indicates UNH's performance is in the upper quartile of its historical performance relative to the S&P 500.  However, this is a relative measure and doesn't guarantee future outperformance.

**Alpha and Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 59.0% | 1.8% | 31.0% | -0.1 | 181.0 |
| 2016-2018  | 66.0% | 10.5% | 47.0% | 0.1 | 207.3 |
| 2017-2019  | 52.0% | 10.5% | 21.0% | 0.4 | 248.8 |
| 2018-2020  | 32.0% | 10.5% | 5.0% | 0.3 | 301.7 |
| 2019-2021  | 96.0% | 9.4% | 25.0% | 0.3 | 438.0 |
| 2020-2022  | 102.0% | 5.5% | 93.0% | 0.3 | 468.4 |
| 2021-2023  | 57.0% | 57.4% | 34.0% | 0.3 | 472.1 |
| 2022-2024  | -26.0% | 57.4% | -59.0% | 0.3 | 460.8 |
| 2023-2025  | -19.0% | 63.2% | -64.0% | 0.1 | 472.8 |

The data shows high CAGR (Compound Annual Growth Rate) in most periods, suggesting strong historical growth.  Beta values generally indicate a higher sensitivity to market movements than the S&P 500 (except 2015-2017).  Alpha values fluctuate, indicating periods of both outperformance and underperformance relative to the market.  The negative CAGR in recent years is a significant concern.


**2) Recent Price Movement:**

* **Closing Price:** $516.85
* **5-Day Moving Average:** $506.83
* **20-Day Moving Average:** $483.47
* **60-Day Moving Average:** $508.44

The price is above all three moving averages, suggesting a short-term uptrend.  However, the gap between the 20-day and 60-day averages is not substantial, implying the uptrend might not be very strong.  The recent price increase of $1.09 (from $511.3) is a relatively small percentage change, and thus not considered a sharp rise.

**3) Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.42 (Medium Risk)
* **RSI:** 80.40 (Overbought territory, suggesting potential for a price correction)
* **PPO:** 1.18 (Positive, indicating bullish momentum)
* **Delta_Previous_Relative_Divergence:** +0.4 (Short-term upward trend)
* **Expected Return (2+ years):** 112.5% (This implies a significant outperformance compared to the S&P 500 over the long term, however, this needs further validation and depends on various market factors).

The high RSI suggests the stock might be overbought, increasing the risk of a short-term correction.  However, the positive PPO and relative divergence show positive momentum. The high expected return is a positive signal, however, it's crucial to remember that this is just a projection and not a guarantee.


**4) Recent Earnings Analysis:**

| Date       | EPS     | Revenue       |
|------------|---------|---------------|
| 2024-11-04 | 6.56    | $100.82 B     |
| 2024-08-09 | 4.58    | $98.86 B     |
| 2024-05-09 | -1.53   | $99.80 B     |
| 2023-11-06 | 6.31    | $92.36 B     |
| 2024-11-04 | 6.31    | $92.36 B     | *(Duplicate entry, likely a data error)*

Revenue remains relatively stable, but EPS shows significant volatility, including a substantial negative EPS in Q2 2024.  This needs further investigation to understand the underlying reasons.  The duplicate entry needs clarification.

**5) Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue      | Profit Margin |
|---------|--------------|---------------|
| 2024-12-31 | $100.81B    | 21.14%        |
| 2024-09-30 | $100.82B    | 22.84%        |
| 2024-06-30 | $98.86B     | 22.31%        |
| 2024-03-31 | $99.80B     | 23.05%        |
| 2023-12-31 | $94.43B     | 23.30%        |


**Capital and Profitability:**

| Quarter | Equity      | ROE           |
|---------|--------------|---------------|
| 2024-12-31 | $92.66B     | 5.98%         |
| 2024-09-30 | $94.53B     | 6.41%         |
| 2024-06-30 | $89.36B     | 4.72%         |
| 2024-03-31 | $86.69B     | -1.63%        |
| 2023-12-31 | $88.76B     | 6.15%         |

Revenue is consistently high, while profit margins are generally strong but show some fluctuation.  ROE is also relatively strong, although it shows a significant negative value in Q1 2024.  Further analysis is required to explain these fluctuations.



**6) Overall Conclusion:**

UNH has historically outperformed the S&P 500, showing high CAGR over several years.  However, recent performance (2022-2024) reveals significant volatility and negative returns. The high RSI suggests potential short-term correction.  The high expected return is promising for long-term investors, but this prediction relies on several assumptions and requires further investigation. The negative EPS and ROE in Q1 and Q2 2024 raise concerns that need to be addressed through further analysis of the company's financial reports and news.  Before any investment decision, a thorough understanding of the reasons for recent volatility is crucial.  Additional analysis of the company's strategic direction and industry trends is recommended.
